喜报！茵冠生物第三款干细胞新药获批临床试验！
R&D
Drug Pipeline
Clinical Translation
Shenzhen Wingor Biotechnology Co., Ltd.
SHENZHEN WINGOR BIOTECHNOLOGY CO.,LTD
Shenzhen Wingor Biotechnology Co., Ltd., established in March 2013, is a national high-tech enterprise dedicated to innovative biopharmaceuticals in the field of cell and gene therapy. The company focuses on unmet clinical needs such as neurological diseases, specializing in innovative cell-based drugs and combination therapies, realizing the entire process from R&D to industrial production. Through continuous innovation, the company empowers industry development, and through cutting-edge exploration, it helps humanity transcend disease boundaries, jointly building a new ecosystem of global health and well-being.
Core Sector
Storing the seeds of life, researching core technologies, illuminating the hope of treatment, and benefiting human health.
R&D
We will build four core technology platforms: stem cells, immune cells, exosomes, and "genetic engineering+", to provide innovation-driven solutions and support for the entire chain from R&D to production.
Drug Pipeline
Guided by clinical value, we innovate and develop novel biopharmaceutical products with high certainty, and have laid out more than ten drug pipelines. Six cell drugs have been accepted for IND applications, three of which have received implied approval for clinical trials from the National Medical Products Administration.
Clinical Translation
We have established long-term strategic partnerships with more than 80 top-tier hospitals in China to jointly promote the clinical translation and project implementation of new biomedical technologies (including stem cells, immune cells, and exosomes).
Cell storage
The South China Integrated Cell Bank adheres to ICH Q5D and the Chinese Pharmacopoeia standards in establishing a tiered cell bank production quality management system to meet the requirements for clinical-grade cell preparation production. It has established partnerships with the obstetrics departments of several top-tier hospitals, enabling it to provide standardized cell resource storage services to the public.
Core Sector
Storing the seeds of life, researching core technologies, illuminating the hope of treatment, and benefiting human health.
R&D
We will build four core technology platforms: stem cells, immune cells, exosomes, and "genetic engineering+", to provide innovation-driven solutions and support for the entire chain from R&D to production.
Drug Pipeline
Guided by clinical value, we innovate and develop novel biopharmaceutical products with high certainty, and have laid out more than ten drug pipelines. Six cell drugs have been accepted for IND applications, three of which have received implied approval for clinical trials from the National Medical Products Administration.
Clinical Translation
We have established long-term strategic partnerships with more than 80 top-tier hospitals in China to jointly promote the clinical translation and project implementation of new biomedical technologies (including stem cells, immune cells, and exosomes).
Cell storage
The South China Integrated Cell Bank adheres to ICH Q5D and the Chinese Pharmacopoeia standards in establishing a tiered cell bank production quality management system to meet the requirements for clinical-grade cell preparation production. It has established partnerships with the obstetrics departments of several top-tier hospitals, enabling it to provide standardized cell resource storage services to the public.
Core advantages
Extensive clinical research experience
Quality Management System
Strictly adhering to international standards followed by organizations such as ISCT (International Society for Cell Therapy), ISSCR (International Society for Stem Cell Research), and AABB (American Association of Blood Banks), we have established a nine-tiered quality control system and a rigorous, orderly stem cell storage process. Through seven indicators and dual testing, we ensure the safety and reliability of every cell sample's original source. Each sample has a sixteen-digit smart code and utilizes a mature serum-free/3D culture system. Every batch of cells leaving the warehouse undergoes 16 indicators and dual testing, achieving full-process quality control in production and preparation. This comprehensively ensures the safety and efficacy of the cells and has earned the accreditation of the National Institutes for Food and Drug Control (NIFDC), the only third-party cell testing institution recognized by top-tier hospitals.
Wingor Scientific Research Achievements
Wingor Biotech has been granted more than 30 cell technology patents, 8 high-tech products, 6 industry standards: industry standards for human adipose stem cell and human dental pulp stem cell preparations, and more than 30 scientific and technological research achievements.
South China Integrated Cell Bank
The Wingor South China Integrated Cell Bank is government-licensed and established with technical support from Shenzhen Wingor Biotechnology Co., Ltd. It has established a rigorous quality management system based on the standards of FDA-CBER OCTGT, FACT, ISCT, ISSCR, and other organizations regarding cell research, preparation, and quality control. It provides cell and tissue storage services to the general public, research teams, and other institutions and organizations.
Partners
Collaborating with over 80 top-tier hospitals in China and renowned research institutions both domestically and internationally, we are jointly conducting basic research and clinical translational applications in the field of cell and gene therapy, contributing to the rapid development of regenerative medicine.
